Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective
AimTo evaluate the cost-effectiveness of palbociclib plus fulvestrant in the second-line treatment of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer based on the latest published follow-up data from the perspective of the Chinese hea...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2023-03-01
|
| 叢編: | Frontiers in Oncology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1068463/full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|